Akebia Therapeutics Inc is a biopharmaceutical company dedicated to developing treatments for kidney diseases. Its main project, Vafseo (vadadustat), targets anemia in chronic kidney disease (CKD) patients, both those undergoing dialysis and those who are not. Additionally, Akebia offers Auryxia, a medication for managing serum phosphorus in dialysis-dependent CKD patients and treating iron deficiency anemia in non-dialysis CKD patients. The company collaborates globally, including with Mitsubishi Tanabe Pharma for vadadustat in Asia. Founded in 2007, Akebia is based in Cambridge, Massachusetts.